NF546 (hydrate)

• UNSPSC Description:

  NF546 (hydrate) is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 (hydrate) stimulates release of interleukin-8 from human monocyte-derived dendritic cells[1].

• Target Antigen:

  P2Y Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/nf546-hydrate.html

• Purity:

  97.4

• Solubility:

  H2O : 12.5 mg/mL (ultrasonic)

• Smiles:

  O=P(O)(O[Na])CC1=C(C=CC(CP(O)(O[Na])=O)=C1)NC(C2=CC(NC(C3=CC(NC(NC4=CC(C(NC5=CC(C(NC6=C(C=C(CP(O)(O[Na])=O)C=C6)CP(O)(O[Na])=O)=O)=CC=C5C)=O)=CC=C4)=O)=CC=C3)=O)=C(C)C=C2)=O.[13.5].O

• Molecular Weight:

  1424.01

• References & Citations:

  [1]Meis S, et al. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther. 2010 Jan;332(1):238-47.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported